36 studies found for:    " September 15, 2010":" October 15, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients
Condition: HIV Positive Patient Receive Implant Supported Restoration
Intervention:
2 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
3 Recruiting Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
4 Active, not recruiting A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
5 Recruiting Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
6 Recruiting R5 Integrase Study in HIV-1 Naive Patients
Condition: HIV Infections
Intervention: Drug: Raltegravir and Maraviroc in combination
7 Unknown  The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Conditions: Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:
8 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
9 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
10 Recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Conditions: Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
11 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
12 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
13 Completed Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
14 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
15 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
16 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
17 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
18 Completed GSK1349572 Hepatic Impairment Study
Conditions: Healthy Subjects;   Hepatic Impairment;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1349572
19 Recruiting ZIAGEN® Post-marketing Surveillance
Condition: Infection, Human Immunodeficiency Virus I
Intervention: Drug: ZIAGEN®
20 Completed A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: Drug: GSK1349572;   Drug: Placebo;   Drug: Iohexol Injection;   Drug: Para-aminohippurate infusion

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years